Serum Circulating microRNA Profiling for Identification of Potential Breast Cancer Biomarkers

Mar‐Aguilar, Fermín; Mendoza-Ramírez, Jorge A.; Malagón-Santiago, Ismael; Espino-Silva, Perla K.; Santuario‐Facio, Sandra K.; Ruíz-Flores, Pablo; Rodríguez‐Padilla, Cristina; Reséndez‐Pérez, Diana

doi:10.1155/2013/259454

Cited by 238 publications

(191 citation statements)

References 38 publications

(41 reference statements)

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…Therefore, we hypothesized that these miRNAs might be candidates for noninvasive breast cancer detection. Overexpression of circulating miR-21-5p has been described in breast cancer patients (27)(28)(29)(30) but also in other cancers such as esophageal, gastric, colorectal, and lung (31 ). This result shows the potential utility of circulating miR-21-5p as a broadspectrum biomarker for the detection of various cancers and not specifically for breast cancer diagnosis.…”

Section: Discussionmentioning

confidence: 83%

“…This result shows the potential utility of circulating miR-21-5p as a broadspectrum biomarker for the detection of various cancers and not specifically for breast cancer diagnosis. MiR125b-5p has also been reported to be upregulated in the serum of breast cancer patients (28,32 ) and has been associated with chemotherapeutic resistance, nonresponsive patients having higher expression levels. Finally, upregulation of miR-96-5p and downregulation of miR-505-5p have been reported in breast tumors and related to increased cell proliferation (33,34 ), but this is the first time that their circulating levels are associated with breast cancer, both being overexpressed.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tumor MicroRNA Expression Profiling Identifies Circulating MicroRNAs for Early Breast Cancer Detection

Vargas²,

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Tumor MicroRNA Expression Profiling Identifies Circulating MicroRNAs for Early Breast Cancer Detection

Vargas²,

et al. 2015

View full text Add to dashboard Cite

show abstract

“…miR-184 was observed to be highly expressed in prostate cancer, while it was significantly downregulated in renal cell carcinoma patients, and was not correlated with patient age and gender or clinical stage of renal cell carcinoma (23). The study by Mar-Aguilar et al confirmed the upregulation of miR-382 in the serum of patients with breast cancer; a sensitivity of 94.40% and a specificity of 90.00% was found for the diagnosis of breast cancer (24). A study by Li et al showed that miR-382-5p expression was significantly downregulated in patients with ductal carcinoma in situ (25), while miR-1246 was demonstrated to exhibit high expression in colorectal cancer (26), esophageal squamous cell carcinoma (27), cervical carcinoma (28), hepatocellular carcinoma (29) and other cancers.…”

Section: A B C Dmentioning

confidence: 95%

Serum expression levels of microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients

Zhu

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. The purpose of the present study was to investigate the serum levels of microRNA (miRNA/miR)-382-3p, -598-3p, -1246 and -184 in breast cancer patients and to assess their feasibility as biomarkers for breast cancer screening. Serum samples were obtained from 100 breast cancer patients and 40 age-matched healthy control subjects in Taizhou Central Hospital (Taizhou, Zhejiang, China) between January 2013 and September 2014. The serum expression levels of miR-382-3p, -598-3p, -1246 and -184 were determined by stem-loop reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic curves were drawn to evaluate the sensitivity and specificity of the serum miRNA expression levels for the screening of breast cancer. miR-382-3p and -1246 were significantly upregulated in the serum of the breast cancer patients, while miR-598-3p and -184 were significantly downregulated. The sensitivity and specificity to detect breast cancer were as follows: miR-382-3p, 52.0 and 92.5%; miR-598-3p, 95.0 and 85.0%; miR-1246, 93.0 and 75.0%; and miR-184, 87.5 and 71.0%, respectively. The expression levels of the four serum miRNAs were not correlated with the patients' clinical stage. In summary, miR-382-3p, -598-3p, -1246 and -184 are all involved in the development of breast cancer, and are promising biomarkers for breast cancer detection. IntroductionBreast cancer has become the most common cancer in women in China, accounting for 12.2% of all newly diagnosed breast cancers and 9.6% of all mortalities from breast cancer worldwide (1). Early detection of breast cancer is the key to successful treatment and patient survival. Mammographies, magnetic resonance imaging and ultrasound are being used for the screening of breast cancer, but these techniques have limitations such as low sensitivity and specificity (2). Finding effective biomarkers is vital for the screening of breast cancer.MicroRNAs (miRNAs/miRs) are a group of small non-coding RNAs (3), which can bind to the 3' untranslated region (UTR), the 5' UTR (4) or the coding region (5) of target mRNA. miRNAs play important roles in the negative regulation of gene expression in a post-transcriptional manner, and are involved in a number of signal transduction pathways, including cell proliferation, differentiation, apoptosis, immune response and angiogenesis (6). Previous studies have revealed the abnormal expression of miRNAs in the development and progression of breast cancer (7), and miRNAs are closely linked with tumor-associated signal transduction pathways (8). In our previous study, 10 miRNAs that were significantly differentially expressed were found by the second generation of high-throughput sequencing technology, Illumina Hiseq2500 (9). In the present study, 4 miRNAs, miR-382-3p, -598-3p, -1246 and -184, were further investigated. The purpose of this study was to investigate the serum levels of these miRNAs in breast cancer patients and to assess their feasibility as biomarkers for breast cancer screening. Materials and methods Subje...

show abstract

“…Multiple studies (Table 3) have demonstrated that miRNA biomarkers provide excellent sensitivity and specificity for detecting early-and even advancedstage breast cancer, strongly suggesting that they are potential diagnostic tools for identifying early and advanced breast cancers [206][207][208][209][210][211][212][213][214][215][216][217][218][219][220][221][222][223][224]. The most commonly reported miRNAs in body fluids and best candidates for biomarkers are miR-21, miR-155, miR-10 b, miR-92 a, miR-133 a, miR-145, miR-148 b and miR-451 [207,[211][212][213][214][215][216][217][219][220][221][222][223]. It is worthy to note that among these identified diagnostic miRNA biomarkers, three miRNAs, including miR-195, miR-145 and miR-451, were reported to be breast cancer specific and can be potentially exploited to distinguish breast cancer from other types of cancer [206,219].…”

Section: Translational Implications Of Ncrnas In Breast Cancermentioning

confidence: 99%

Noncoding RNAs in breast cancer

Lo¹,

Wolfson²,

Zhou³

et al. 2015

Briefings in Functional Genomics

View full text Add to dashboard Cite

The mammalian transcriptome has recently been revealed to encompass a large number of noncoding RNAs (ncRNAs) that play a variety of important regulatory roles in gene expression and other biological processes. MicroRNAs (miRNAs), the best studied of the short noncoding RNAs (sncRNAs), have been extensively characterized with regard to their biogenesis, function and importance in tumorigenesis. Another class of sncRNAs called piwi-interacting RNAs (piRNAs) has also gained attention recently in cancer research owing to their critical role in stem cell regulation. Long noncoding RNAs (lncRNAs) of >200 nucleotides in length have recently emerged as key regulators of developmental processes, including mammary gland development. lncRNA dysregulation has also been implicated in the development of various cancers, including breast cancer. In this review, we describe and discuss the roles of sncRNAs (including miRNAs and piRNAs) and lncRNAs in the initiation and progression of breast tumorigenesis, with a focus on outlining the molecular mechanisms of oncogenic and tumor-suppressor ncRNAs. Moreover, the current and potential future applications of ncRNAs to clinical breast cancer research are also discussed, with an emphasis on ncRNA-based diagnosis, prognosis and future therapeutics.

show abstract

Serum Circulating microRNA Profiling for Identification of Potential Breast Cancer Biomarkers

Cited by 238 publications

References 38 publications

Tumor MicroRNA Expression Profiling Identifies Circulating MicroRNAs for Early Breast Cancer Detection

Tumor MicroRNA Expression Profiling Identifies Circulating MicroRNAs for Early Breast Cancer Detection

Serum expression levels of microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients

Noncoding RNAs in breast cancer

Contact Info

Product

Resources

About